Octreotide LAR: safety and tolerability issues.

Octreotide LAR: safety and tolerability issues.

Item
http://www.wikidata.org/entity/Q37649647
Somatostatin analogues for treatment of enterocutaneous fistulaCorrelation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.Poor pregnancy outcome after octreotide treatment during pregnancy for familial hyperinsulinemic hypoglycemia: a case report.Long-acting somatostatin analogues provide significant beneficial effect in patients with refractory small bowel angiodysplasia: Results from a proof of concept open label mono-centre trialCluster Headache: Special Considerations for Treatment of Female Patients of Reproductive Age and Pediatric Patients.Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension.Chylous ascites occurring after low anterior resection of the rectum successfully treated with an oral fat-free elemental diet (Elental(®))Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies.
P2860

Octreotide LAR: safety and tolerability issues.

Item
http://www.wikidata.org/entity/Q37649647
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Octreotide LAR: safety and tolerability issues.
@en
Octreotide LAR: safety and tolerability issues.
@nl
type
label
Octreotide LAR: safety and tolerability issues.
@en
Octreotide LAR: safety and tolerability issues.
@nl
prefLabel
Octreotide LAR: safety and tolerability issues.
@en
Octreotide LAR: safety and tolerability issues.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Octreotide LAR: safety and tolerability issues.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698